Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin and Sino Universal Sign Deal for Tiotropium DPI Supply in China
Details : Under the licensing agreement, SUP will holds the right for the commercialization of Spiriva HandiHaler-Generic (Tiotropium Bromide) in the Chinese market for the treatment of COPD.
Product Name : Spiriva HandiHaler-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 16, 2025
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement